SPY380.36-1.97 -0.52%
DIA309.45-4.53 -1.44%
IXIC13,192.35+72.96 0.56%

DJ Health Care Roundup: Market Talk

· 02/06/2021 04:20

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

2011 GMT - The S&P has its best week since early November as investors continue to bet on a fresh coronairus-relief package following another downbeat monthly jobs report. The Senate approves a budget plan that advances the reconciliation process necessary to get President Biden's aid plan approved with a simple majority. Johnson & Johnson gains 1.5% after it asked US regulators to authorize the emergency use of its Covid-19 vaccine. DJIA gains 92 points to 31148, the S&P 500 adds 15 to 3886, and the Nasdaq rises 78 to 13856. The S&P and Nasdaq mark new all-time highs. (patrick.sullivan@wsj.com)

1404 GMT - Ziopharm Oncology adds WaterMill Asset Management founder Robert Postma to its board as part of a settlement agreement with the activist investor. Watermill won two board seats, along with the ouster of then chairman Scott Tarriff, in a consent solicitation in December, but a cap on board membership at eight kept Postma from a third WaterMill seat. Ziopharm says it's expanding the board to nine and adding Postma as part of the standstill deal, and that it will reimburse WaterMill for up to $400,000 in costs related to its efforts. (colin.kellaher@wsj.com)

1359 GMT - Regeneron continues to see barriers to patients getting its Covid-19 antibody drug, both in doctors prescribing it and in allowing people to easily get it when it is prescribed, says CEO Leonard Schleifer on 4Q earnings call. "We need to do work at all ends of the funnel," he says, but things are starting to get better. In some cases, medical-record algorithms are alerting doctors that their patients are eligible to take the drug after testing positive and meeting certain-risk factor requirements, says Dr. Schleifer. But some doctors who are aware of the drugs remain skeptical that there isn't yet enough data to support its use, he says. Regeneron shares gain 0.7% on the day, but are 19% lower over the past six months. (joseph.walker@wsj.com)

(END) Dow Jones Newswires

February 06, 2021 04:20 ET (09:20 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.